This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Birrer, M. J. Articles by Geradts, J. Search for Related Content PubMed PubMed Citation Articles by Birrer, M. J. Articles by Geradts, J.

Abnormal Fhit Expression in Malignant and Premalignant Lesions of the Cervix

Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Rockville, Maryland 20850

Genetic analysis of cervical cancer has demonstrated frequent allelic loss in the 3p chromosomal region. The newly described gene FHIT is located at chromosome region 3p14.2, and its expression has been demonstrated previously by reverse transcription-PCR to be abnormal in a majority of cervical cancer cell lines. In this study, 98 different lesions of the cervix were examined for Fhit expression by immunohistochemical staining. Whereas normal cervical epithelium demonstrated diffuse, moderate to intense cytoplasmic staining, many pathological lesions of the cervix displayed reduced or absent Fhit expression. Sixty-one percent of squamous carcinomas and 40% of adenocarcinomas of the cervix had abnormal Fhit expression. Sixty-five preneoplastic lesions of the cervix were examined. Eleven of 33 high-grade squamous intraepithelial lesions and 1 of 12 low-grade squamous intraepithelial lesions had abnormal Fhit expression. In summary, Fhit expression is frequently abnormal in both glandular and squamous cervical cancers, with a higher frequency of Fhit alterations observed in squamous lesions. In addition, abnormal Fhit expression can be detected in some preneoplastic lesions of the ectocervix. Alterations in Fhit expression may be an important marker of early progression in the development of cancers of the cervix.

This article has been cited by other articles:

				O. Kujan, R. Oliver, L. Roz, G. Sozzi, N. Ribeiro, R. Woodwards, N. Thakker, and P. Sloan Fragile Histidine Triad Expression in Oral Squamous Cell Carcinoma and Precursor Lesions. Clin. Cancer Res., November 15, 2006; 12(22): 6723 - 6729. [Abstract] [Full Text] [PDF]

				J. S. Lea, R. Ashfaq, S. Muneer, D. G. Burbee, D. S. Miller, J. D. Minna, and C. Y. Muller Understanding the Mechanisms of FHIT Inactivation in Cervical Cancer for Biomarker Development Reproductive Sciences, July 1, 2004; 11(5): 329 - 337. [Abstract] [PDF]

				I. I. Wistuba, R. Ashfaq, A. Maitra, H. Alvarez, E. Riquelme, and A. F. Gazdar Fragile Histidine Triad Gene Abnormalities in the Pathogenesis of Gallbladder Carcinoma Am. J. Pathol., June 1, 2002; 160(6): 2073 - 2079. [Abstract] [Full Text] [PDF]

				K. Uematsu, A. Yoshimura, A. Gemma, H. Mochimaru, Y. Hosoya, S. Kunugi, K. Matsuda, M. Seike, F. Kurimoto, K. Takenaka, et al. Aberrations in the Fragile Histidine Triad (FHIT) Gene in Idiopathic Pulmonary Fibrosis Cancer Res., December 1, 2001; 61(23): 8527 - 8533. [Abstract] [Full Text] [PDF]

				H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF]

				F.-S. Liu, J.-T. Chen, J.-T. Dong, Y.-T. Hsieh, A.-J. Lin, E. Shih-Chu Ho, M.-J. Hung, and C.-H. Lu KAI1 Metastasis Suppressor Gene Is Frequently Down-Regulated in Cervical Carcinoma Am. J. Pathol., November 1, 2001; 159(5): 1629 - 1634. [Abstract] [Full Text] [PDF]

				N. Zanesi, V. Fidanza, L. Y. Fong, R. Mancini, T. Druck, M. Valtieri, T. Rudiger, P. A. McCue, C. M. Croce, and K. Huebner The tumor spectrum in FHIT-deficient mice PNAS, August 17, 2001; (2001) 191345898. [Abstract] [Full Text] [PDF]

				T. C. Krivak, J. W. McBroom, J. Seidman, D. Venzon, B. Crothers, P. J. MacKoul, G. S. Rose, J. W. Carlson, and M. J. Birrer Abnormal Fragile Histidine Triad (FHIT) Expression in Advanced Cervical Carcinoma: A Poor Prognostic Factor Cancer Res., June 1, 2001; 61(11): 4382 - 4385. [Abstract] [Full Text] [PDF]

				A. Vecchione, N. Zanesi, G. Trombetta, D. French, P. Visca, T. Pisani, C. Botti, A. Vecchione, C. M. Croce, and R. Mancini Cervical Dysplasia, Ploidy, and Human Papillomavirus Status Correlate with Loss of Fhit Expression Clin. Cancer Res., May 1, 2001; 7(5): 1306 - 1312. [Abstract] [Full Text]

				D. C. Connolly, D. L. Greenspan, R. Wu, X. Ren, R. L. Dunn, K. V. Shah, R. W. Jones, F. X. Bosch, N. Muñoz, and K. R. Cho Loss of Fhit Expression in Invasive Cervical Carcinomas and Intraepithelial Lesions Associated with Invasive Disease Clin. Cancer Res., September 1, 2000; 6(9): 3505 - 3510. [Abstract] [Full Text]

				Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax Expression in Invasive and in Situ Squamous Cell Carcinoma of the Uterine Cervix Clin. Cancer Res., September 1, 2000; 6(9): 3600 - 3606. [Abstract] [Full Text]

				R. Wu, D. C. Connolly, R. L. Dunn, and K. R. Cho Restored Expression of Fragile Histidine Triad Protein and Tumorigenicity of Cervical Carcinoma Cells J Natl Cancer Inst, February 16, 2000; 92(4): 338 - 344. [Abstract] [Full Text] [PDF]

				X. P. Hao, J. E. Willis, T. G. Pretlow, J. S. Rao, G. T. MacLennan, I. C. Talbot, and T. P. Pretlow Loss of Fragile Histidine Triad Expression in Colorectal Carcinomas and Premalignant Lesions Cancer Res., January 1, 2000; 60(1): 18 - 21. [Abstract] [Full Text]

				N. Zanesi, V. Fidanza, L. Y. Fong, R. Mancini, T. Druck, M. Valtieri, T. Rudiger, P. A. McCue, C. M. Croce, and K. Huebner The tumor spectrum in FHIT-deficient mice PNAS, August 28, 2001; 98(18): 10250 - 10255. [Abstract] [Full Text] [PDF]